Qsymia for weight loss is the brand name for phentermine-topiramate extended-release, an oral pill FDA-approved in 2012 for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition like hypertension or type 2 diabetes. It works through appetite suppression and a mild metabolic effect from two older drug classes, not the incretin biology behind GLP-1 injections, so its results, side effects, and disqualifying conditions look nothing like Wegovy or Zepbound. If a previous provider put you on it, or you're deciding between an oral option and an injection before you enroll anywhere, this is what the label and the trial data actually say.
GoodLife Health's clinical protocols don't include Qsymia in the standard formulary — the weight loss medications for patients who can't take GLP-1s page covers what does get prescribed instead. This guide exists so you can read the real data on Qsymia before a decision, not a sales pitch for it.
- Qsymia for weight loss combines phentermine and topiramate; the CONQUER trial showed 10.2% weight loss at the top dose vs 1.6% on placebo.
- Best for adults without cardiovascular disease, glaucoma, or pregnancy plans who want a daily pill instead of an injection.
- Common side effects: tingling in hands and feet, dry mouth, insomnia, and a metallic taste with carbonated drinks.
- GLP-1 medications like Zepbound and Wegovy produce larger average weight loss and skip Qsymia's pregnancy category X warning.
- A Biomarker Audit determines whether an oral agent or a GLP-1 protocol fits a given metabolic profile better.
Why this matters
Qsymia predates the GLP-1 era by roughly a decade, and it's still on the market because it works for a specific patient — someone who wants a pill, not a weekly injection, and who doesn't carry the contraindications that rule it out. The problem is that most people researching it in 2026 are comparing it against Wegovy and Zepbound headlines without knowing the actual trial numbers or the safety warnings that come with an anticonvulsant-based combination drug.
GoodLife Health treats weight loss as one piece of a larger cardiometabolic system — insulin, lipids, hormones, and inflammation all move together, which is why the Cardiometabolic Optimization Membership runs a full Biomarker Audit before any medication decision. That framing matters here too: whether Qsymia, phentermine alone, or a GLP-1 is the right call depends on labs and history, not on which drug has the loudest marketing.
Who Qsymia for weight loss actually helps
Qsymia's FDA label targets a narrower group than most people assume. It's built for adults who meet the BMI threshold, have no history of cardiovascular events, aren't pregnant or planning pregnancy, and don't have glaucoma or hyperthyroidism. Within that group, it tends to suit patients who've tried phentermine alone with partial results and want the added topiramate effect, or who specifically want to avoid needles.
It does not suit patients managing type 2 diabetes primarily through weight loss, since GLP-1 medications carry stronger glycemic evidence, nor does it suit anyone on an MAOI or with a recent stroke or heart attack. Kidney stone history is another flag, since topiramate raises stone risk.
Confirm you meet the FDA eligibility criteria
Before anything else, check the label's actual thresholds against your own history:
- BMI of 30+, or 27+ with hypertension, type 2 diabetes, or high cholesterol
- Age 18 or older
- No pregnancy, no plan to conceive, and willingness to use contraception if you can become pregnant
- No history of glaucoma, hyperthyroidism, recent stroke, or unstable heart disease
- No MAOI use within the past 14 days
- No known kidney stone disorder without a prior workup
Get baseline labs and a cardiovascular check before day one
Qsymia isn't a start-and-go prescription. A responsible prescriber orders:
- Resting heart rate and blood pressure, since phentermine can raise both
- A pregnancy test for anyone of reproductive potential, repeated monthly during the early months per the REMS program
- Kidney function and electrolyte panel, since topiramate can cause metabolic acidosis
- A review of current SSRIs, stimulants, and thyroid medications for interaction risk
- Baseline weight and waist circumference to track response
A pregnancy test is required before starting and repeated monthly during the early treatment months per the REMS program, and kidney function and electrolytes should be checked at baseline since topiramate can cause metabolic acidosis.
Follow the four-step titration schedule
Qsymia doesn't start at full strength. The label builds the dose over roughly three months:
- Weeks 1-2: 3.75 mg phentermine / 23 mg topiramate once daily
- Weeks 3-14: 7.5 mg / 46 mg once daily
- If less than 3% weight loss by week 12: step up to 11.25 mg / 69 mg for two weeks
- Top dose: 15 mg / 92 mg once daily if the mid-dose isn't enough
The FDA's stopping rule is specific and often skipped by patients who don't read the label: if you haven't lost at least 5% of your body weight by week 12 on the top dose, the drug is meant to be discontinued because further response is unlikely.
If a patient hasn't lost at least 5% of body weight by week 12 on the top dose, the label calls for discontinuation because further response is unlikely — this checkpoint should be treated as a hard stop, not a suggestion.
Track side effects week by week
Most Qsymia side effects show up early and either fade or persist depending on dose. Watch for:
- Paresthesia — tingling or numbness in the hands and feet, the most commonly reported side effect
- Dry mouth and constipation
- Insomnia or jitteriness, tied to the phentermine component
- Dysgeusia — a metallic taste, especially with carbonated beverages
- Word-finding difficulty or trouble concentrating, tied to topiramate
- Elevated heart rate, which needs monitoring if you have any cardiac history
Build the lifestyle layer around the pill
Qsymia is labeled as an adjunct to diet and exercise, not a replacement for either:
- Keep a calorie deficit; the drug suppresses appetite but doesn't create one on its own
- Increase water intake to offset dry mouth and constipation
- Limit alcohol, since it compounds the CNS effects of both drug components
- Hit a consistent protein target to protect lean mass during the deficit
- Never stop abruptly at higher doses — taper under supervision to avoid topiramate withdrawal effects
Know when Qsymia isn't the right fit — and what replaces it
Patients who stall before the 5% checkpoint, who develop cognitive side effects they can't tolerate, or who have cardiovascular risk factors that surface after starting are the ones who need a different plan. This is where the conversation usually shifts to GLP-1 therapy. Branded, FDA-approved options — Wegovy, Zepbound, Ozempic, and Mounjaro — work through a different mechanism entirely and post larger average results: roughly 15% body weight in the STEP-1 semaglutide trial and up to 22.5% in SURMOUNT-1 for tirzepatide, though individual results vary.
Under GoodLife Health's clinical protocols, physicians licensed in all 50 states review the quarterly Biomarker Audit — ApoB, Lp(a), hs-CRP, HbA1c, and full hormone and thyroid panels — before recommending an oral agent, a GLP-1, or a combination approach. For patients who specifically don't qualify for or don't want a GLP-1, the phentermine option for adults who don't qualify for GLP-1 medications outlines what that path looks like without the topiramate combination.
Qsymia vs. the alternatives
Qsymia vs. the alternatives
| Option | Best for | Key limitation |
|---|---|---|
| Qsymia (phentermine-topiramate) | Adults wanting a daily pill with no cardiovascular disease or pregnancy plans | Category X pregnancy risk requires monthly testing; cognitive side effects in a subset of patients |
| Contrave (naltrexone-bupropion) | Patients with food-noise or binge patterns who can't take stimulant-based drugs | Contraindicated with seizure disorder and uncontrolled hypertension; more modest average weight loss |
| Phentermine alone | Short-term appetite suppression without the topiramate side effect profile | Approved for short-term use only; less total weight loss than the combination |
| GLP-1 medications (Wegovy vs. Zepbound comparison) | Adults wanting the largest average weight loss with weekly dosing | Requires injection; GI side effects like nausea during dose escalation |
Qsymia is a reasonable oral option for adults who fit the narrow eligibility profile and specifically want to avoid injections — but for most adults with obesity and no contraindications, GLP-1 therapy now produces meaningfully larger average results.
Common mistakes patients make with Qsymia
- Stopping cold turkey. Abrupt discontinuation at the higher doses skips the taper the label recommends and can trigger withdrawal effects tied to the topiramate component.
- Skipping the monthly pregnancy test. The REMS program requires it during the early treatment months for anyone of reproductive potential; skipping it isn't a paperwork issue, it's a safety requirement given the category X risk.
- Blaming the drug for a bad taste instead of adjusting habits. The metallic dysgeusia is triggered specifically by carbonated beverages for a lot of patients — cutting soda often resolves it without stopping the medication.
- Quitting before the 12-week checkpoint. Some patients give up in month one, before the titration schedule even reaches the dose where response is actually measured.
- Stacking it with other stimulants or high caffeine intake. This compounds the heart rate and blood pressure effects the label already flags as a risk.
Anyone evaluating options more broadly should look at the medical weight loss clinic for adults with obesity overview before locking into one drug class.
FAQ
What is Qsymia for weight loss and how does it work?
Qsymia is the brand name for phentermine-topiramate extended-release, an oral combination pill that suppresses appetite through two mechanisms rather than the GLP-1 pathway used by Wegovy or Zepbound. It's FDA-approved as an adjunct to diet and exercise for chronic weight management.
Who qualifies for Qsymia?
Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition like hypertension or type 2 diabetes, qualify under the FDA label. Pregnancy, glaucoma, hyperthyroidism, and recent cardiovascular events rule it out.
How much weight can you lose on Qsymia?
In the CONQUER trial, patients on the top dose lost an average of 10.2% of body weight over 56 weeks compared with 1.6% on placebo. Individual results vary and depend on adherence to the lifestyle component of treatment.
What are the most common Qsymia side effects?
Tingling in the hands and feet, dry mouth, insomnia, constipation, and a metallic taste with carbonated drinks are the most reported effects. A smaller group of patients experiences cognitive side effects like word-finding difficulty.
Can you take Qsymia if you're trying to get pregnant?
No. Qsymia is pregnancy category X and can cause oral clefts in a developing fetus, so it requires a negative pregnancy test before starting and monthly testing during the early treatment period for anyone who can become pregnant.
Is Qsymia better than Wegovy or Zepbound?
Not on average weight loss. GLP-1 trials report roughly 15% body weight loss for semaglutide and up to 22.5% for tirzepatide, both larger than Qsymia's 10.2% top-dose result, though Qsymia avoids injections entirely.
How long do you stay on Qsymia?
The FDA label includes a stopping rule: if you haven't lost 5% of your body weight by week 12 on the top dose, the medication should be discontinued because further benefit is unlikely. Patients who respond typically continue as long as it's tolerated and effective.
Does insurance cover Qsymia?
Coverage varies significantly by plan, and many formularies exclude weight-loss medications entirely regardless of drug class. Checking your specific plan's weight-management drug coverage before starting is the only reliable way to know.
One last thing
The detail most patients miss is the FDA's own 12-week stopping rule at the top dose: if Qsymia hasn't produced 5% weight loss by then, the label says to discontinue it rather than keep waiting for it to kick in. That single checkpoint is worth more than any headline comparison to GLP-1 drugs, because it tells you within three months whether the medication is working for your body specifically, not the trial average.
Related guides
- Best GLP-1 medications for weight loss in 2026
- How to choose a medical weight loss program
- Best weight loss medications for patients who fear needles
- How to start medical weight loss with a doctor
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/